China SXT Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About China SXT Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
China SXT Pharmaceuticals, Inc. operates as a pharmaceutical company focused on traditional Chinese medicine pieces. Through its operating subsidiaries and variable interest entity, the company engages in the research, development, manufacture, and distribution of regular and advanced traditional Chinese medicine piece products. It also participates in tourism town development projects and related commercial activities. The company primarily markets and distributes its medicinal products to pharmaceutical clinics, hospitals, and commercial customers.
The company conducts its core business operations within the People's Republic of China and Hong Kong. Its operational footprint includes leased and owned facilities such as office spaces, warehouses, and specialized manufacturing equipment. Corporate operations and executive management are based at its principal executive offices located at 178 Taidong Road North in Taizhou, Jiangsu Province, China.
Summary of the business section of China SXT Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- China SXT Pharmaceuticals, Inc.
- Headquarters
- Taizhou, China
- Address
- 178 Taidong Road North
- Phone
- 8652386298290
- Employees
- 56, Mar 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- D8
- Fiscal year ends
- March 31
- Auditor
- Enrome LLP, Singapore
Stock & identifiers
- Ticker
- SXTC
- Exchange
- Nasdaq
- IPO date
- Oct 3, 2018
- Shares outstanding
- 1M, Mar 31, 2026
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-80 reverse, Aug 10, 2026; 1-for-150 reverse, Feb 3, 2026; 1-for-25 reverse, Oct 5, 2023; 1-for-4 reverse, Aug 13, 2021; 1-for-4 reverse, Feb 22, 2021
- SEC CIK
- 1723980
- CUSIP
- G2161P157
- ISIN
- USG2161P1574
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Feng Felix Zhou | Co-CEO and Director | 4 |
| Xiaodong Sean Pan | Chief Financial Officer | – |
| Lim Sze Beng Simon | Co-Chief Executive Officer | – |
| Jun Zheng | Director | – |
| Tong Tony Liu | Director | – |
| Yong Lip Chee | Director | – |
| Xiaodong Ji | Director | – |
Employees
Headcount reported in annual reports
“had a total of 56 full-time employees and no part-time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2024 | Late filing | Notification of late filing |
| Aug 2, 2021 | Late filing | Notification of late filing |
| Jul 31, 2019 | Late filing | Notification of late filing |
| Dec 26, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 3, 2018 | IPO | Initial public offering priced (424B4 prospectus) |